Key result
Tailored antithrombotic therapy in PAD requires balancing thrombotic and bleeding risks across arterial beds.
Why the study?
PAD patients face high atherothrombotic risk across heterogeneous vascular territories, yet clinical data have traditionally derived from coronary artery disease trials, highlighting the need to assess current evidence for tailored antithrombotic management.
This review summarizes current evidence for tailored antithrombotic management in patients with peripheral artery disease across different arterial beds.
No takes yet. Share an insight, caveat, or question.
Individualized antithrombotic decisions in PAD warrant bed-specific risk evaluation; leaves open optimal regimens pending prospective trials.
Canonico et al. (2023) conducted a review in Peripheral artery disease. Antithrombotic therapy was evaluated. Tailored antithrombotic therapy in peripheral artery disease requires careful assessment of thrombotic and hemorrhagic risks across different arterial beds to optimize secondary prevention.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: